Bank of America Downgrades Leidos Rating and Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 hours ago
0mins
Source: NASDAQ.COM
- Rating Downgrade: Bank of America downgraded Leidos from Buy to Neutral and cut its price target from $200 to $125, reflecting concerns over its healthcare business, particularly increased pressure from the Defense Health Agency.
- Stock Price Decline: Following a flat trading week, Leidos shares fell 11% this week, prompting investors to sell off due to the downgrade, which significantly impacted the stock's performance.
- Financial Health: Despite the downgrade, Leidos maintains a strong financial position with high profitability and no debt, closing at $113.58, which implies a 10% upside to Bank of America's target price, indicating potential investment value.
- Market Reaction Excessive: While Bank of America's concerns are notable, the market's reaction appears excessive, with Leidos trading at a trailing P/E of 10, significantly below its five-year average of 20.6, suggesting a favorable entry point for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LDOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LDOS
Wall Street analysts forecast LDOS stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 108.670
Low
178.00
Averages
219.70
High
235.00
Current: 108.670
Low
178.00
Averages
219.70
High
235.00
About LDOS
Leidos Holdings, Inc. is a holding company, which operates through its wholly owned subsidiary, Leidos, Inc. (Leidos). The Company's segments include National Security & Digital, Health & Civil, Commercial & International and Defense Systems. Its National Security & Digital business provides technologically advanced services, solutions and products, as well as mission software capabilities for defense and intelligence customers in the areas of cyber, logistics, security operations and decision analytics. Its Health & Civil business provides services and solutions to federal and commercial customers in the areas of public health, care coordination, life and environmental sciences and transportation. Its Commercial & International business delivers a portfolio of products, services, and solutions aimed at securing national assets, modernizing energy and critical infrastructure, and enhancing mission outcomes. The Company serves government and commercial customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Leidos Shares Plummet Following Price Target Downgrade
- Significant Price Drop: Leidos shares fell notably this week, dropping 11% from last Friday's close, indicating investor concerns about the company's future prospects after a period of flat trading.
- Price Target Downgrade: Bank of America downgraded Leidos from Buy to Neutral and cut its price target from $200 to $125, primarily due to expectations of increasing pressure on its healthcare business, reflecting a reassessment of the company's health.
- Healthcare Business Pressure: While Leidos's managed healthcare segment has been strong, Bank of America believes that the Defense Health Agency is now working directly with suppliers, which may increase pressure on Leidos's healthcare portfolio and impact future profitability.
- Investment Opportunity Analysis: Despite the downward pressure, Leidos remains financially healthy with a current share price of $107.12 and a P/E ratio of 10, which is below the five-year average of 20.6, potentially presenting an attractive buying opportunity for investors.
See More
Bank of America Downgrades Leidos Rating and Price Target
- Rating Downgrade: Bank of America downgraded Leidos from Buy to Neutral and cut its price target from $200 to $125, reflecting concerns over its healthcare business, particularly increased pressure from the Defense Health Agency.
- Stock Price Decline: Following a flat trading week, Leidos shares fell 11% this week, prompting investors to sell off due to the downgrade, which significantly impacted the stock's performance.
- Financial Health: Despite the downgrade, Leidos maintains a strong financial position with high profitability and no debt, closing at $113.58, which implies a 10% upside to Bank of America's target price, indicating potential investment value.
- Market Reaction Excessive: While Bank of America's concerns are notable, the market's reaction appears excessive, with Leidos trading at a trailing P/E of 10, significantly below its five-year average of 20.6, suggesting a favorable entry point for investors.
See More
US Stocks Plunge as Tech Sector Weighs Down Market
- Market Weakness: On Wednesday, the S&P 500 Index fell by 1.21%, the Dow Jones Industrial Average dropped by 0.98%, and the Nasdaq 100 Index declined by 0.99%, reflecting market concerns over potential interest rate hikes by the Fed, particularly amid weak performance in technology stocks.
- Economic Data Support: Despite the market downturn, US May retail sales rose by 0.9% month-over-month, surpassing expectations of 0.6%, indicating resilient consumer demand, while pending home sales increased by 3.8% month-over-month, marking the largest gain in 20 months, potentially providing some support to the market.
- Fed Policy Outlook: The Fed maintained interest rates at its meeting on Wednesday but indicated through its dot plot that at least one more 25 basis point hike is expected this year, with the 2026 year-end federal funds rate projection raised to 3.75%, reflecting a cautious outlook on future economic conditions.
- International Market Response: While US stocks declined, overseas markets performed strongly, with the Euro Stoxx 50 reaching a new record high and closing up 0.68%, demonstrating global investor confidence in economic recovery, which may contrast with the US market's performance.
See More
Mixed Performance in US Stock Indices, Chipmakers Lead Gains
- Strong Economic Data: US May retail sales rose 0.9% month-over-month, exceeding expectations of 0.6%, indicating resilient consumer demand that could positively impact future spending and economic recovery.
- Housing Market Recovery: Pending home sales in May increased by 3.8% month-over-month, significantly surpassing the expected 0.9%, marking the largest gain in 20 months, suggesting a rebound in the real estate market that may stimulate growth in related sectors.
- Oil Price Volatility: The agreement between the US and Iran to reopen the Strait of Hormuz has driven crude oil prices down to a 3.5-month low, increasing risk-on sentiment in the market, which may lead investors to reassess the risks and returns of energy-related assets.
- FOMC Meeting Focus: The market anticipates that the Federal Reserve will keep interest rates unchanged, but the press conference by new Chair Kevin Warsh will be pivotal, as investors closely watch his outlook on inflation to guide future investment decisions.
See More
U.S. Stocks Rise, Led by Chipmakers Amid Strong Retail Sales
- Strong Market Performance: The S&P 500 index rose by 0.23%, the Dow Jones Industrial Average increased by 0.26%, and the Nasdaq 100 climbed by 0.74%, reflecting market confidence in economic recovery, particularly driven by strong performances from chipmakers.
- Retail Sales Exceed Expectations: U.S. May retail sales increased by 0.9% month-over-month, surpassing the expected 0.6%, indicating resilient consumer demand that could further stimulate economic growth and influence future monetary policy.
- Oil Price Decline Affects Market Sentiment: The agreement between the U.S. and Iran to reopen the Strait of Hormuz has led to crude oil prices dropping to a 3.5-month low, enhancing risk-on sentiment in the markets and contributing to stock gains.
- FOMC Meeting in Focus: Market participants are closely watching the outcome of the FOMC meeting, where interest rates are expected to remain unchanged, but the guidance from new Chair Kevin Warsh will significantly impact market sentiment.
See More
BofA Downgrades Leidos Amid Healthcare Pressures Clouding Defense Prospects
- Rating Downgrade: Bank of America downgraded Leidos from Buy to Neutral, primarily due to pressures in its healthcare business and uncertainty surrounding the company's overall portfolio transformation, which is expected to negatively impact stock performance.
- Healthcare Business Challenges: Leidos' managed healthcare operations, once a strong performer, may see reduced roles in the DHMSM program as the Defense Health Agency seeks direct supplier engagement, potentially hindering future growth prospects.
- Market Share Risks: The upcoming recompete of the MDE contract could weaken Leidos' market share and pricing power; analysts noted that while the company recently secured the Military OneSource contract, increasing competition in the sector may limit future growth opportunities.
- Strategic Confidence Issues: Despite expanding energy infrastructure ambitions through the acquisition of ENTRUST and a joint venture with Analogic, analysts express skepticism regarding the effectiveness of Leidos' NorthStar 2030 strategy, emphasizing the need for the company to demonstrate that its portfolio changes can deliver sustained growth.
See More
Leidos Shares Plummet Following Price Target Downgrade
- Significant Price Drop: Leidos shares fell notably this week, dropping 11% from last Friday's close, indicating investor concerns about the company's future prospects after a period of flat trading.
- Price Target Downgrade: Bank of America downgraded Leidos from Buy to Neutral and cut its price target from $200 to $125, primarily due to expectations of increasing pressure on its healthcare business, reflecting a reassessment of the company's health.
- Healthcare Business Pressure: While Leidos's managed healthcare segment has been strong, Bank of America believes that the Defense Health Agency is now working directly with suppliers, which may increase pressure on Leidos's healthcare portfolio and impact future profitability.
- Investment Opportunity Analysis: Despite the downward pressure, Leidos remains financially healthy with a current share price of $107.12 and a P/E ratio of 10, which is below the five-year average of 20.6, potentially presenting an attractive buying opportunity for investors.
See More
Bank of America Downgrades Leidos Rating and Price Target
- Rating Downgrade: Bank of America downgraded Leidos from Buy to Neutral and cut its price target from $200 to $125, reflecting concerns over its healthcare business, particularly increased pressure from the Defense Health Agency.
- Stock Price Decline: Following a flat trading week, Leidos shares fell 11% this week, prompting investors to sell off due to the downgrade, which significantly impacted the stock's performance.
- Financial Health: Despite the downgrade, Leidos maintains a strong financial position with high profitability and no debt, closing at $113.58, which implies a 10% upside to Bank of America's target price, indicating potential investment value.
- Market Reaction Excessive: While Bank of America's concerns are notable, the market's reaction appears excessive, with Leidos trading at a trailing P/E of 10, significantly below its five-year average of 20.6, suggesting a favorable entry point for investors.
See More
US Stocks Plunge as Tech Sector Weighs Down Market
- Market Weakness: On Wednesday, the S&P 500 Index fell by 1.21%, the Dow Jones Industrial Average dropped by 0.98%, and the Nasdaq 100 Index declined by 0.99%, reflecting market concerns over potential interest rate hikes by the Fed, particularly amid weak performance in technology stocks.
- Economic Data Support: Despite the market downturn, US May retail sales rose by 0.9% month-over-month, surpassing expectations of 0.6%, indicating resilient consumer demand, while pending home sales increased by 3.8% month-over-month, marking the largest gain in 20 months, potentially providing some support to the market.
- Fed Policy Outlook: The Fed maintained interest rates at its meeting on Wednesday but indicated through its dot plot that at least one more 25 basis point hike is expected this year, with the 2026 year-end federal funds rate projection raised to 3.75%, reflecting a cautious outlook on future economic conditions.
- International Market Response: While US stocks declined, overseas markets performed strongly, with the Euro Stoxx 50 reaching a new record high and closing up 0.68%, demonstrating global investor confidence in economic recovery, which may contrast with the US market's performance.
See More
Mixed Performance in US Stock Indices, Chipmakers Lead Gains
- Strong Economic Data: US May retail sales rose 0.9% month-over-month, exceeding expectations of 0.6%, indicating resilient consumer demand that could positively impact future spending and economic recovery.
- Housing Market Recovery: Pending home sales in May increased by 3.8% month-over-month, significantly surpassing the expected 0.9%, marking the largest gain in 20 months, suggesting a rebound in the real estate market that may stimulate growth in related sectors.
- Oil Price Volatility: The agreement between the US and Iran to reopen the Strait of Hormuz has driven crude oil prices down to a 3.5-month low, increasing risk-on sentiment in the market, which may lead investors to reassess the risks and returns of energy-related assets.
- FOMC Meeting Focus: The market anticipates that the Federal Reserve will keep interest rates unchanged, but the press conference by new Chair Kevin Warsh will be pivotal, as investors closely watch his outlook on inflation to guide future investment decisions.
See More
U.S. Stocks Rise, Led by Chipmakers Amid Strong Retail Sales
- Strong Market Performance: The S&P 500 index rose by 0.23%, the Dow Jones Industrial Average increased by 0.26%, and the Nasdaq 100 climbed by 0.74%, reflecting market confidence in economic recovery, particularly driven by strong performances from chipmakers.
- Retail Sales Exceed Expectations: U.S. May retail sales increased by 0.9% month-over-month, surpassing the expected 0.6%, indicating resilient consumer demand that could further stimulate economic growth and influence future monetary policy.
- Oil Price Decline Affects Market Sentiment: The agreement between the U.S. and Iran to reopen the Strait of Hormuz has led to crude oil prices dropping to a 3.5-month low, enhancing risk-on sentiment in the markets and contributing to stock gains.
- FOMC Meeting in Focus: Market participants are closely watching the outcome of the FOMC meeting, where interest rates are expected to remain unchanged, but the guidance from new Chair Kevin Warsh will significantly impact market sentiment.
See More
BofA Downgrades Leidos Amid Healthcare Pressures Clouding Defense Prospects
- Rating Downgrade: Bank of America downgraded Leidos from Buy to Neutral, primarily due to pressures in its healthcare business and uncertainty surrounding the company's overall portfolio transformation, which is expected to negatively impact stock performance.
- Healthcare Business Challenges: Leidos' managed healthcare operations, once a strong performer, may see reduced roles in the DHMSM program as the Defense Health Agency seeks direct supplier engagement, potentially hindering future growth prospects.
- Market Share Risks: The upcoming recompete of the MDE contract could weaken Leidos' market share and pricing power; analysts noted that while the company recently secured the Military OneSource contract, increasing competition in the sector may limit future growth opportunities.
- Strategic Confidence Issues: Despite expanding energy infrastructure ambitions through the acquisition of ENTRUST and a joint venture with Analogic, analysts express skepticism regarding the effectiveness of Leidos' NorthStar 2030 strategy, emphasizing the need for the company to demonstrate that its portfolio changes can deliver sustained growth.
See More
